Jinling Pharmaceutical Company Limited (SHE:000919)
China flag China · Delayed Price · Currency is CNY
6.19
-0.06 (-0.96%)
Jul 30, 2026, 3:04 PM CST

SHE:000919 Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Net Income
58.9453.9140.41106.19105.28120.63
Depreciation & Amortization
148.09148.09160.92151.2124.34122.95
Other Amortization
25.6725.678.27.066.045.31
Loss (Gain) From Sale of Assets
0.390.39-21.340.56-62.58-51.98
Asset Writedown & Restructuring Costs
18.9618.9696.320.150.8447.53
Loss (Gain) From Sale of Investments
-30.09-30.09-54-32.1112.262.86
Provision & Write-off of Bad Debts
0.010.011.763.21.66-1.67
Other Operating Activities
35.71-15.99-19.9224.059.1535.27
Change in Accounts Receivable
5.125.12-90.6388.99-56.17-107.93
Change in Inventory
37.4637.4618.79-27.947.99-30.04
Change in Accounts Payable
-63.49-63.4911.01-100.18129.54148.97
Change in Other Net Operating Assets
-3.46-3.46----
Operating Cash Flow
230.92174.21154.19212.02260.59292.03
Operating Cash Flow Growth
29.12%12.98%-27.28%-18.64%-10.76%-6.24%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Capital Expenditures
-87.13-157.87-201.63-237.88-309.64-162.76
Sale of Property, Plant & Equipment
6.690.1222.123.6780.0664.93
Cash Acquisitions
---261.2--21.77-
Divestitures
------1.25
Investment in Securities
-149.13-188.79-313.9-276.434.890.56
Other Investing Activities
33.2937.1336.9240.7425.3529.4
Investing Cash Flow
-196.28-309.41-717.7-449.89-221.11-69.12

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Short-Term Debt Issued
----1.9615
Long-Term Debt Issued
--1500.31--
Total Debt Issued
--1500.311.9615
Long-Term Debt Repaid
--1.26-3.96-5.01-22.83-1.37
Net Debt Issued (Repaid)
-1.26-1.26146.04-4.7-20.8613.63
Issuance of Common Stock
--7443.3823.62-
Repurchase of Common Stock
-6.08-6.08-18.76---
Common Dividends Paid
-68.4-67.51-63.24-51.16-51.16-50.66
Other Financing Activities
-9.98-10.22-1.628.932.15-2.61
Financing Cash Flow
-85.71-85.08806.42-43.55-46.26-39.65

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Foreign Exchange Rate Adjustments
-00.010.040.020.08-0
Net Cash Flow
-51.07-220.26242.94-281.4-6.71183.26

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
143.7916.34-47.44-25.85-49.05129.26
Free Cash Flow Growth
-----544.48%
Free Cash Flow Margin
4.56%0.51%-1.45%-0.81%-1.84%4.60%
Free Cash Flow Per Share
0.230.03-0.08-0.05-0.100.26
Levered Free Cash Flow
148.160.14-80.212.52-134.9555.68
Unlevered Free Cash Flow
151.613.4-78.8313.33-134.7955.86

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Cash Income Tax Paid
111.49102.3192.04128.0297.66104.08
Change in Working Capital
-26.74-26.74-58.16-48.2763.611.12